Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Elsevier Business Intelligence

14:33 EDT 17th October 2018 | BioPortfolio

Here are the most relevant search results for "Elsevier Business Intelligence" found in our extensive news archives from over 250 global news sources.

More Information about Elsevier Business Intelligence on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Elsevier Business Intelligence for you to read. Along with our medical data and news we also list Elsevier Business Intelligence Clinical Trials, which are updated daily. BioPortfolio also has a large database of Elsevier Business Intelligence Companies for you to search.

Showing News Articles 1–25 of 1,800+ from Elsevier Business Intelligence

Tuesday 16th October 2018

Sitryx Therapeutics raises $30mm through Series A round

Sitryx Therapeutics (autoimmune/inflammatory and oncology treatments) raised $30mm through its Series A round. Sofinnova Part...

Series A brings $4.4mm to LogicBio; $444k added

LogicBio Therapeutics Inc. raised $4.4mm through its Series A round from OrbiMed Advisors and Leland Stanford Junior Universi...

LogicBio files for initial public offering

LogicBio Therapeutics Inc. (gene editing) filed for its initial public offering.

Jnana, Neurocrine enter discovery pact for small-molecule CNS disorder therapeutics

Jnana Therapeutics Inc. and Neurocrine Biosciences Inc. are allying to discover multiple targets from which to develop small-...

Series C brings in €6.5mm for LNC Therapeutics

LNC Therapeutics (developing therapies for obesity and related cardiometabolic diseases) raised €6.5mm ($7.7mm) in its Seri...

Glympse Bio gets $6.6mm in seed funding

MIT spin-out Glympse Bio Inc. raised $6.6mm in seed funding from Biocon India and Aspect Ventures. The recently-formed compan...

LNC Therapeutics gets IP from Cornell

LNC Therapeutics licensed exclusive rights to Christensenella patents from Cornell University.

Glympse Bio raises $22mm through Series A round

Diagnostics firm Glympse Bio Inc. raised $22mm through its Series A round that was co-led by LS Polaris Innovation Fund and A...

Sarepta gains ex-European license to Lysogene's LYS-SAF302 MPS IIIA gene therapy candidate

Sarepta Therapeutics Inc. licensed exclusive worldwide commercialization (except in Europe) and manufacturing rights to Lysog...

AmpliPhi nets $6.2mm via FOPO

AmpliPhi Biosciences Corp. (therapies for antibiotic-resistant bacterial infections) netted $6.2mm via a follow-on public off...

Synthetic Biologics nets $17.3mm via FOPO

Synthetic Biologics Inc. (therapeutics focused on the gut microbiome) netted $17.3mm through the public offering of 2.52mm Cl...

Curetis secures up to €20mm in convertible debt financing

Curetis NV (molecular diagnostics for infectious diseases) secured up to €20mm ($23.2mm) in convertible debt financing with...

Dermatology start-up Hoth Therapeutics files for IPO

Hoth Therapeutics Inc. (technology that creates a topical agent from existing therapeutics to treat skin diseases) filed for ...

EMA Aims To Carry On With EU GMP Annex 1 Revision Despite Brexit-Related Staff Departures

The European Medicines Agency is continuing to work on revising Annex 1 of the EU GMP guideline even as the...  ...

J&J Supports ‘Spirit’ Of DTC Pricing Transparency, But Prefers PhRMA’s Voluntary Approach

Leading off the third quarter earnings calls for biopharma, J&J offered mild support of a proposed HHS policy to require....

Evaluation Of Commercial ELISA Kit For Quantification Of Alkaline Stabilized Protein A, The SuRe Ligand

In industrial monoclonal antibody production affinity chromatagraphy with protein A is usually applied as the first purificat...

ICER Is Weighing Early Research Consulting Work With Pharma

The drug value assessment organization said it is considering whether or not to move forward with a program to consult......

Submit Your Brexit-Related Changes Before We Move: EMA Plea To industry

A continuous two-way dialogue on Brexit between the European Medicines Agency and industry is a must. The EMA is tentatively....

EU Policymakers Under Industry Pressure To 'Neuter' SPC Waiver Plan

“Vested interests” are pressuring EU policymakers to water down further European Commission plans for an exemption intend...

Takhzyro Among Hopefuls For EU Approval Recommendation

A handful of companies are expected to find out this week whether their products will be recommended for EU approval... ...

Monday 15th October 2018

Adynxx reverse merges with Alliqua, taking the latter's public listing to advance pain pipeline

Private biotech Adynxx Inc. (non-opioid pain and inflammation therapeutics) agreed to reverse-merge with publicly traded Alli...

Public offering nets $206mm for Iovance

Iovance Biotherapeutics Inc. (cancer immunotherapies) netted $206mm via a public offering of 22mm common shares at $9.97. Som...

Blueberry Therapeutics closes £10mm Series B round

Blueberry Therapeutics Ltd. (nanomedicines for dermatology indications) completed a £10mm ($12.8mm) Series B round from Chin...

Verastem nets $146mm through RDO of convertible senior notes

Verastem Inc. (aka Verastem Oncology; developing cancer therapeutics) netted $146mm through a registered direct offering of $...

Study On Patient Support Program Impact Piques EMA's Interest

The pharmaceutical industry's renewed effort to find a pragmatic solution to managing adverse events from patient support...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks